Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1975 5
1976 2
1977 1
1978 8
1979 1
1980 6
1981 4
1982 3
1983 2
1984 1
1985 3
1986 6
1987 1
1988 3
1989 2
1991 1
1993 2
1994 2
1996 2
1997 2
1998 2
2000 2
2001 1
2002 2
2003 1
2004 1
2005 3
2006 6
2007 1
2008 3
2009 2
2011 1
2012 3
2013 4
2014 2
2015 1
2017 8
2018 8
2019 5
2020 8
2021 8
2022 1
2023 3
2024 3
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Desoximetasone.
[No authors listed] [No authors listed] 2021 Jan 18. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2021 Jan 18. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000806 Free Books & Documents. Review.
Desoximetasone has not been studied during breastfeeding. Since only extensive application of the most potent corticosteroids cause systemic effects in the mother, it is unlikely that short-term application of topical corticosteroids would pose a risk to the breastfed infa …
Desoximetasone has not been studied during breastfeeding. Since only extensive application of the most potent corticosteroids cause s …
Drugs for atopic dermatitis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2026 Mar 2;68(1749):33-40. doi: 10.58347/tml.2026.1749a. Med Lett Drugs Ther. 2026. PMID: 41730175 No abstract available.
Drugs for atopic dermatitis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Jun 15;62(1600):89-96. Med Lett Drugs Ther. 2020. PMID: 32555122 No abstract available.
A Comparative Evaluation of Desoximetasone Cream and Ointment Formulations Using Experiments and In Silico Modeling.
Matharoo NS, Garimella HT, German C, Przekwas AJ, Michniak-Kohn B. Matharoo NS, et al. Int J Mol Sci. 2023 Oct 12;24(20):15118. doi: 10.3390/ijms242015118. Int J Mol Sci. 2023. PMID: 37894801 Free PMC article.
The proposed approach was demonstrated through a study involving Desoximetasone cream and ointment formulations, where the release kinetics and permeation profiles of Desoximetasone were determined experimentally, and a computational model was created to simulate th …
The proposed approach was demonstrated through a study involving Desoximetasone cream and ointment formulations, where the release ki …
A Promising Approach to Treat Psoriasis: Inhibiting Cytochrome P450 3A4 Metabolism to Enhance Desoximetasone Therapy.
Guo JW, Cheng YP, Lim CJ, Liu CY, Jee SH. Guo JW, et al. Pharmaceutics. 2023 Jul 25;15(8):2016. doi: 10.3390/pharmaceutics15082016. Pharmaceutics. 2023. PMID: 37631230 Free PMC article.
In this study, we aimed to investigate the anti-psoriatic effect of a low dose of desoximetasone by inhibiting cytochrome P450 3A4 metabolism in the epidermis. (2) Methods: Psoriasis-like skin was induced in BALB/c mice via the topical administration of imiquimod. The mice …
In this study, we aimed to investigate the anti-psoriatic effect of a low dose of desoximetasone by inhibiting cytochrome P450 3A4 me …
Desoximetasone 0.25% Spray for the Relief of Scaling in Adults With Plaque Psoriasis.
Keegan BR. Keegan BR. J Drugs Dermatol. 2015 Aug;14(8):835-40. J Drugs Dermatol. 2015. PMID: 26267727 Clinical Trial.
At the baseline visit, the mean proportions of BSA affected by psoriasis were 17% (range 10% to 86%) in the desoximetasone 0.25% spray group and 16% (range 10% to 70%) in the vehicle spray group. Approximately 90% of the patients in each group had moderate to very severe s …
At the baseline visit, the mean proportions of BSA affected by psoriasis were 17% (range 10% to 86%) in the desoximetasone 0.25% spra …
Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis.
Hebert AA, Koo J, Fowler J, Berman B, Rosenberg C, Levitt J. Hebert AA, et al. Cutis. 2006 Nov;78(5):357-63. Cutis. 2006. PMID: 17186796 Clinical Trial.
Long-term in vitro compatibility of desoximetasone and tacrolimus ointments prompted the current trial in humans. We aimed to evaluate the efficacy of twice-daily simultaneous application of desoximetasone and tacrolimus in the treatment of atopic dermatitis versus …
Long-term in vitro compatibility of desoximetasone and tacrolimus ointments prompted the current trial in humans. We aimed to evaluat …
Efficacy and Safety of Desoximetasone 0.25% Spray in Adult Atopic Dermatitis Subjects: Pilot Study.
Hoffman LK, Kircik L. Hoffman LK, et al. J Drugs Dermatol. 2017 Sep 1;16(9):919-922. J Drugs Dermatol. 2017. PMID: 28915287 Clinical Trial.
STUDY DESIGN: A single-center, open labeled pilot study was conducted to investigate the efficacy and safety of desoximetasone 0.25% spray for pruritus in adult atopic dermatitis patients. RESULTS: Twice daily application of desoximetasone 0.25% spray to affected ar …
STUDY DESIGN: A single-center, open labeled pilot study was conducted to investigate the efficacy and safety of desoximetasone 0.25% …
Sakuranetin modulates IL-17A-related inflammation and enhances skin barrier function in an imiquimod-induced psoriasis model.
Chen YC, Cheng YP, Liu CY, Wang WC, Wang TM, Lai CY, Guo JW. Chen YC, et al. Biomed Pharmacother. 2025 May;186:118035. doi: 10.1016/j.biopha.2025.118035. Epub 2025 Apr 9. Biomed Pharmacother. 2025. PMID: 40209307 Free article.
Topical administration of sakuranetin significantly attenuated psoriatic inflammation, with high-dose treatment achieving comparable efficacy to desoximetasone. RNA sequencing and qPCR validation revealed that sakuranetin modulates keratinization, cornified envelope format …
Topical administration of sakuranetin significantly attenuated psoriatic inflammation, with high-dose treatment achieving comparable efficac …
Topical Desoximetasone 0.25% Spray and Its Vehicle Have Little Potential for Irritation or Sensitization.
Nadkarni A, Saleem MD, Feldman SR. Nadkarni A, et al. J Drugs Dermatol. 2017 Aug 1;16(8):755-758. J Drugs Dermatol. 2017. PMID: 28809990 Clinical Trial.

OBJECTIVE: To evaluate the irritation and sensitization potential of topical desoximetasone spray formulation.</p> <p>METHODS: A multicenter, double-blinded, randomized, controlled study assessed the irritancy and sensitization of 0.25% and …

OBJECTIVE: To evaluate the irritation and sensitization potential of topical desoximetasone spray formulation.&lt …

128 results